Shares of IperionX Limited Sponsored ADR (NASDAQ:IPX – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $46.50.
A number of equities research analysts recently weighed in on IPX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of IperionX in a research note on Friday, July 17th. BTIG Research raised their price objective on shares of IperionX from $40.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 5th. Jefferies Financial Group began coverage on shares of IperionX in a research report on Wednesday, September 2nd. They set a “buy” rating and a $26.00 target price for the company. Finally, Roth Capital set a $53.00 price target on IperionX in a research report on Wednesday, August 5th.
View Our Latest Report on IperionX
IperionX Price Performance
Insider Transactions at IperionX
In other news, Chairman Todd Hannigan purchased 300,000 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The shares were acquired at an average cost of $3.59 per share, for a total transaction of $1,077,000.00. Following the transaction, the chairman directly owned 26,633,334 shares of the company’s stock, valued at approximately $95,613,669.06. The trade was a 1.14% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Anastasios Arima acquired 138,720 shares of IperionX stock in a transaction that occurred on Friday, July 10th. The shares were purchased at an average cost of $3.58 per share, for a total transaction of $496,617.60. Following the purchase, the chief executive officer directly owned 12,455,502 shares in the company, valued at $44,590,697.16. The trade was a 1.13% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 663,720 shares of company stock worth $2,379,118.
Institutional Investors Weigh In On IperionX
Large investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in IperionX by 40.3% in the second quarter. GAMMA Investing LLC now owns 1,681 shares of the company’s stock worth $50,000 after purchasing an additional 483 shares during the period. Connective Capital Management LLC acquired a new position in shares of IperionX in the 2nd quarter valued at $160,000. XY Capital Ltd acquired a new position in shares of IperionX in the 4th quarter valued at $290,000. DLD Asset Management LP bought a new stake in shares of IperionX in the 1st quarter valued at $260,000. Finally, Corigliano Investment Advisers LLC bought a new stake in shares of IperionX in the 4th quarter valued at $362,000. Institutional investors own 2.76% of the company’s stock.
IperionX Company Profile
IperionX Limited (NASDAQ: IPX) is a materials technology company focused on developing a low-carbon, fully integrated titanium supply chain in the United States. The company is working to produce titanium metal and titanium products from locally sourced mineral resources, with applications across the aerospace, defense, automotive, medical and consumer industries.
IperionX’s flagship asset is the Titan Project in Tennessee, which contains titanium, rare earth and zircon-rich mineral sands.
Further Reading
- Five stocks we like better than IperionX
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for IperionX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IperionX and related companies with MarketBeat.com's FREE daily email newsletter.
